Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership on May 17, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.87 CNY | +0.17% | +9.00% | -15.70% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.70% | 561M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 603520 Stock
- News Zhejiang Starry Pharmaceutical Co.,Ltd.
- Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership.